Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) — Cash Flow-to-Debt Ratio
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has a Cash Flow-to-Debt Ratio of 0.29x as of December 2025, meaning its operating cash flow of $41.05 Million could theoretically repay 0% of its total liabilities ($140.71 Million) in one year. See Zhengye Biotechnology Holding Limited Or (ZYBT) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zhengye Biotechnology Holding Limited Ordinary Shares Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Zhengye Biotechnology Holding Limited Ordinary Shares across 5 annual periods. For the full cash flow conversion analysis, see Zhengye Biotechnology Holding Limited Or (ZYBT) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)
Year-by-year debt coverage analysis for Zhengye Biotechnology Holding Limited Ordinary Shares. Check Zhengye Biotechnology Holding Limited Or earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | $41.05 Million | $140.71 Million | ▲ +0.0% |
| 2024 | 0.29x | $41.05 Million | $140.71 Million | ▼ -2.8% |
| 2023 | 0.30x | $48.18 Million | $160.62 Million | ▲ +181.7% |
| 2022 | 0.11x | $17.34 Million | $162.81 Million | ▼ -57.7% |
| 2021 | 0.25x | $31.81 Million | $126.44 Million | — |